Zobrazeno 1 - 10
of 59
pro vyhledávání: '"Andrea Ferrante"'
Autor:
Andrzej M. Kierzek, Timothy P. Hickling, Isabel Figueroa, J. Cory Kalvass, Marjoleen Nijsen, Krithika Mohan, Geertruida M. Veldman, Akihiro Yamada, Hiroyuki Sayama, Sachiko Yokoo, Abhishek Gulati, Renu S. Dhanikula, Jochem Gokemeijer, Tarek A. Leil, Craig J. Thalhauser, Mario Giorgi, Maciej J. Swat, Vijayalakshmi Chelliah, Ben G. Small, Neil Benson, Michael Walker, Kapil Gadkar, Valerie Quarmby, Rong Deng, Andrea Ferrante, Gemma L. Dickinson, Jan‐Stefan Van Der Walt, Lian Zhou, Xiaoying Chen, Hannah M. Jones, Jatin Narula, Sophie Tourdot, Thierry Lavé, Benjamin Ribba, Piet H. van derGraaf
Publikováno v:
CPT: Pharmacometrics & Systems Pharmacology, Vol 8, Iss 11, Pp 773-776 (2019)
Externí odkaz:
https://doaj.org/article/368f598c595b469b8b9deb6681ea6d5a
A structure-based engineering approach to abrogate pre-existing antibody binding to biotherapeutics.
Autor:
Joanne Lin, Stacey L Lee, Anna M Russell, Rong Fong Huang, Micheal A Batt, Shawn S Chang, Andrea Ferrante, Petra Verdino
Publikováno v:
PLoS ONE, Vol 16, Iss 7, p e0254944 (2021)
Development of biotherapeutics is hampered by the inherent risk of immunogenicity, which requires extensive clinical assessment and possible re-engineering efforts for mitigation. The focus in the pre-clinical phase is to determine the likelihood of
Externí odkaz:
https://doaj.org/article/b3a2ef3195954b0488eb8607de448e39
Autor:
Robin E. Walsh, Megan Lannan, Yi Wen, Xiaoli Wang, Christopher A. Moreland, Jill Willency, Michael D. Knierman, Laura Spindler, Ling Liu, Wei Zeng, Guilherme V. Rocha, Victor Obungu, Jirong Lu, Arunan Kaliyaperumal, Andrea Ferrante, Robert Siegel, Laurent P. Malherbe
Publikováno v:
mAbs, Vol 12, Iss 1 (2020)
Biologics have the potential to induce an immune response when used therapeutically. A number of in vitro assays are currently used preclinically to predict the risk of immunogenicity, but the validation of these preclinical tools suffers from the re
Externí odkaz:
https://doaj.org/article/28841672b87f4adda992076575ebfe5a
Publikováno v:
PLoS ONE, Vol 3, Iss 11, p e3722 (2008)
HLA-DM (DM) mediates exchange of peptides bound to MHC class II (MHCII) during the epitope selection process. Although DM has been shown to have two activities, peptide release and MHC class II refolding, a clear characterization of the mechanism by
Externí odkaz:
https://doaj.org/article/9f01952b845e470388f7a6f638969609
Autor:
Arunan Kaliyaperumal, Yi Wen, Andrea Ferrante, Carina Torres, Suntara Cahya, Candyd Velasquez, Paul Anderson, Xiaoli Wang
Publikováno v:
Journal of immunological methods. 498
Immunogenicity is one major challenge to the successful development of biotherapeutics because it could adversely affect PK/PD, safety, and efficacy. Preclinical immunogenicity risk assessment strategies and assays have been developed and implemented
Autor:
Lorrie D. Rea, Brittany Wilhite, Todd M. O'Hara, Andrea Ferrante, J. Margaret Castellini, Thomas Kuhn, Stephanie N. Kennedy
Publikováno v:
Journal of Immunological Methods. 462:42-47
Immunoglobulins (Ig) are proteins that preserve immune homeostasis and are quantified to infer changes to the acquired humoral immune response in mammals. Measuring Ig in non-model wildlife for immune surveillance often requires ingenuity, and rigoro
Autor:
Micheal A. Batt, Joanne Lin, Andrea Ferrante, Petra Verdino, Anna Maria Russell, Shawn Chang, Stacey Lynn Lee, Rong Fong Huang
Publikováno v:
PLoS ONE, Vol 16, Iss 7, p e0254944 (2021)
PLoS ONE
PLoS ONE
Development of biotherapeutics is hampered by the inherent risk of immunogenicity, which requires extensive clinical assessment and possible re-engineering efforts for mitigation. The focus in the pre-clinical phase is to determine the likelihood of
Autor:
Wei Zeng, Robert W. Siegel, Xiaoli Wang, Yi Wen, Ling Liu, Laurent Malherbe, Andrea Ferrante, Suntara Cahya, Joanne Lin, Arunan Kaliyaperumal
Publikováno v:
The AAPS Journal. 22
Treatment-emergent antidrug antibodies (TE-ADA) pose a major challenge to the development of biotherapeutics. The antidrug antibody responses are highly orchestrated and involve many types of immune cells and biological processes. Biological drug int
Autor:
Michael D. Knierman, Ling Liu, Megan B. Lannan, Christopher A. Moreland, Yi Wen, Laura J. Spindler, Jill A. Willency, Victor H. Obungu, Andrea Ferrante, Robert W. Siegel, Robin E. Walsh, Arunan Kaliyaperumal, Guilherme Rocha, Jirong Lu, Laurent Malherbe, Xiaoli Wang, Wei Zeng
Publikováno v:
mAbs
article-version (VoR) Version of Record
article-version (VoR) Version of Record
Biologics have the potential to induce an immune response when used therapeutically. A number of in vitro assays are currently used preclinically to predict the risk of immunogenicity, but the validation of these preclinical tools suffers from the re
Autor:
Andrea Ferrante, Lian Zhou, Marjoleen Nijsen, J. Cory Kalvass, Renu S Dhanikula, Gemma L. Dickinson, Piet H. van der Graaf, Isabel Figueroa, Kapil Gadkar, Andrzej M. Kierzek, Neil Benson, Akihiro Yamada, Michael Walker, Benjamin Ribba, Thierry Lavé, Sophie Tourdot, Jan-Stefan van der Walt, Abhishek Gulati, Hiroyuki Sayama, Jatin Narula, Valerie Quarmby, Vijayalakshmi Chelliah, Ben G Small, Xiaoying Chen, Rong Deng, Sachiko Yokoo, Maciej J. Swat, Craig J. Thalhauser, Krithika Mohan, Hannah M. Jones, Geertruida M. Veldman, Timothy P. Hickling, Jochem Gokemeijer, Mario Giorgi, Tarek A. Leil
Publikováno v:
CPT Pharmacometrics Syst Pharmacol
CPT: Pharmacometrics & Systems Pharmacology, Vol 8, Iss 11, Pp 773-776 (2019)
CPT: Pharmacometrics & Systems Pharmacology
CPT: Pharmacometrics & Systems Pharmacology, Vol 8, Iss 11, Pp 773-776 (2019)
CPT: Pharmacometrics & Systems Pharmacology
Immunogenicity is a major challenge in drug development and patient care. Currently, most efforts are dedicated to the elimination of the unwanted immune responses through T‐cell epitope prediction and protein engineering. However, because it is un
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1101d65d4d512bb2b5d4501d81dc7645
https://eprints.whiterose.ac.uk/153749/1/Kierzek_et_al-2019-CPT__Pharmacometrics_&_Systems_Pharmacology.pdf
https://eprints.whiterose.ac.uk/153749/1/Kierzek_et_al-2019-CPT__Pharmacometrics_&_Systems_Pharmacology.pdf